Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. Its products include disposable blood perfusion devices, disposable plasma bilirubin adsorbers, DNA immunoadsorption column and blood purification equipment. The company offers products for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders. Jafron Biomedica was founded on December 19, 1989 and is headquartered in Zhuhai, China.

Sanofi Pasteur Ltd. develops, manufactures, and markets vaccines and immunotherapeutic products. It offers vaccines for haemophilus influenza type B (Hib), diphtheria, pertussis, poliomyelitis, tetanus, hepatitis A, influenza, poliomyelitis, rabies, meningococcal disease, typhoid fever, and yellow fever, as well as oncology products for bladder cancers. The company was founded John Gerald FitzGerald in 1914 and is headquartered in Toronto, Canada.

NIPD Genetics Ltd., a subsidiary of Medicover AB, is a company headquartered in Nicosia, Cyprus, that operates as biotechnology company. The firm was founded in 2010 by Philippos C. Patsalis, who is currently the CEO of the firm. Medicover AB acquired NIPD Genetics Ltd. on January 18, 2022 for $50.32 million.

THP is an emerging biotechnology company focused on research in the field of human antibody technologies. THP has developed a unique transgenic mammalian platform to create human antibodies. The technology will enable the generation of both monoclonal and polyclonal antibody therapeutics with enhanced efficacy.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Adprotech is a biopharmaceutical company, develops pharmaceutical products for the treatment of organ transplant rejection, rheumatoid arthritis, bacterial infection, and stroke diseases. It develops and applies Prodaptin, a platform technology that increases the efficacy of therapeutics by targeting specific cells or tissues.

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have clinically demonstrated that DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, demonstrated it destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 90% of anal cancer, and 69% of vulvar cancer.

LG Life Sciences Ltd. engages in the development, production and marketing medicine and fine chemicals. Its products include growth hormone products, arthritis medicine, diabetes medicine, cosmetic surgery products, hypertension treatment, synthetic medicinal raw materials, and pesticide raw material. The company was founded on August 1, 2002 and is headquartered in Seoul, South Korea.

Keryos SpA manufactures pharmaceutical products. The firm also sells chemicals. The company is headquartered in Gessate, Italy.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Life Sciences, Inc. is an American private company located in St. Petersburg, FL, involved in surgical and medical instruments and apparatus. It was founded by Roderick N. Carter.\nThe company says this about itself: Ichor Life Sciences is a premium preclinical contract research organization offering services in discovery through pharmacology. The company operates R&D laboratories in LaFayette and Potsdam, N.Y., including an AAALAC-accredited vivarium. Services are provided through two divisions. Ichor Discovery Services provides world-class protein manufacturing, as well as a full suite of capabilities in structural biology, biophysics, and assay development. Ichor Pharmacology Services offers in vitro testing, histology, PK/PD, in vivo toxicology, and in vivo efficacy capabilities. Therapeutic areas served by Ichor Life Sciences include oncology, metabolic disease, musculoskeletal disease, ophthalmology, and geriatrics. Ichor Life Sciences was founded in 2013 and is headquartered in New York's Finger Lakes intellectual corridor.

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.